This article provides a comprehensive overview of chemogenomic library screening and its pivotal role in advancing precision oncology.
This article provides a comprehensive overview of target-family focused library design, a strategic approach in drug discovery that creates compound collections tailored to interact with specific protein families.
Phenotypic Drug Discovery (PDD) has re-emerged as a powerful strategy for identifying first-in-class therapeutics, yet its success is critically dependent on the quality of the compound libraries screened.
This article provides a comprehensive comparative analysis of chemogenomic library design strategies employed by leading pharmaceutical organizations Pfizer and GlaxoSmithKline (GSK), alongside the National Center for Advancing Translational Sciences (NCATS).
This article provides a comprehensive framework for researchers and drug development professionals to evaluate the biological potency of compounds across diverse screening libraries.
This article provides a comprehensive guide for researchers and drug development professionals on the application of chemogenomic libraries for validating the mechanism of action (MoA) of small molecules.
This article provides a comprehensive comparison of target-based and phenotypic screening strategies in modern drug discovery.
This article provides a comprehensive benchmark analysis of modern chemogenomic library design strategies, addressing the critical needs of researchers and drug development professionals.
Selecting the optimal screening library is a critical, early-stage decision in drug discovery that significantly impacts project timelines, costs, and success.
This article provides a comprehensive analysis for researchers and drug development professionals on the strategic choice between chemogenomic libraries and diverse compound sets for screening campaigns.